JP2019529560A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529560A5
JP2019529560A5 JP2019537047A JP2019537047A JP2019529560A5 JP 2019529560 A5 JP2019529560 A5 JP 2019529560A5 JP 2019537047 A JP2019537047 A JP 2019537047A JP 2019537047 A JP2019537047 A JP 2019537047A JP 2019529560 A5 JP2019529560 A5 JP 2019529560A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
patient
csa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537047A
Other languages
English (en)
Japanese (ja)
Other versions
JP7164530B2 (ja
JP2019529560A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052772 external-priority patent/WO2018057776A1/en
Publication of JP2019529560A publication Critical patent/JP2019529560A/ja
Publication of JP2019529560A5 publication Critical patent/JP2019529560A5/ja
Priority to JP2022128592A priority Critical patent/JP2022160685A/ja
Application granted granted Critical
Publication of JP7164530B2 publication Critical patent/JP7164530B2/ja
Priority to JP2024153668A priority patent/JP2024174962A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537047A 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 Active JP7164530B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022128592A JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662397988P 2016-09-22 2016-09-22
US62/397,988 2016-09-22
US201762442083P 2017-01-04 2017-01-04
US62/442,083 2017-01-04
US201762443819P 2017-01-09 2017-01-09
US62/443,819 2017-01-09
US201762445774P 2017-01-13 2017-01-13
US62/445,774 2017-01-13
US201762519896P 2017-06-15 2017-06-15
US62/519,896 2017-06-15
EP17306081 2017-08-18
EP17306081.5 2017-08-18
PCT/US2017/052772 WO2018057776A1 (en) 2016-09-22 2017-09-21 Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022128592A Division JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Publications (3)

Publication Number Publication Date
JP2019529560A JP2019529560A (ja) 2019-10-17
JP2019529560A5 true JP2019529560A5 (enExample) 2020-10-22
JP7164530B2 JP7164530B2 (ja) 2022-11-01

Family

ID=59974890

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019537047A Active JP7164530B2 (ja) 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2022128592A Pending JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A Pending JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022128592A Pending JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A Pending JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Country Status (13)

Country Link
US (1) US20220110999A1 (enExample)
EP (2) EP3515465B1 (enExample)
JP (3) JP7164530B2 (enExample)
KR (3) KR20190053250A (enExample)
CN (2) CN118203659A (enExample)
AU (2) AU2017332732B2 (enExample)
CA (1) CA3037499A1 (enExample)
ES (1) ES2974376T3 (enExample)
HU (1) HUE066662T2 (enExample)
IL (2) IL265516B2 (enExample)
MX (3) MX2019003235A (enExample)
PL (1) PL3515465T3 (enExample)
RU (1) RU2759630C2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
CN116981692A (zh) * 2021-01-14 2023-10-31 翻译生物公司 递送mRNA编码的抗体的方法和组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
US6896906B2 (en) * 2000-12-21 2005-05-24 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008054606A2 (en) 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r

Similar Documents

Publication Publication Date Title
JP2019529560A5 (enExample)
JP2025172841A5 (enExample)
RU2019111921A (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
JP2022160685A5 (enExample)
CN106062000B (zh) 通过施用il-4r拮抗剂治疗皮肤感染的方法
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
HRP20181227T1 (hr) Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
RU2019103943A (ru) Применение антагонистов il-13 для лечения атопического дерматита
JP2017507139A5 (enExample)
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
JP2016523863A5 (enExample)
JP2017512193A5 (enExample)
EP3487881B1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2017511316A5 (enExample)
Choy et al. Mepolizumab (Nucala) for severe eosinophilic asthma
TW202045537A (zh) 化膿性汗腺炎的治療
AU2023265133A1 (en) Il-13 antibodies for the treatment of atopic dermatitis
JPWO2021026205A5 (enExample)
JPWO2019222055A5 (enExample)
Rommer et al. Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions
JPWO2021195530A5 (enExample)
JP2019535716A5 (enExample)
HRP20191709T1 (hr) Postupci liječenja nosne polipoze davanjem antagonista il-4r
EP4126943A1 (en) Methods for treating atopic dermatitis and related disorders
RU2020140639A (ru) Способы лечения атопического дерматита посредством введения ингибитора ил-4r